FY24 consensus $3.10. Raises FY24 revenue growth view to up 7%-8% from up 6%-7% on a constant-currency basis, consensus $1.22B. When excluding the impact of the ACS segment wind down, the company now expects revenue for full-year 2024 to grow between 9% and 10% on a constant-currency basis, up from prior view of 8%-9%. Foreign currency is expected to be a 1% headwind based on current exchange rates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LIVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- LivaNova price target raised to $72 from $70 at Stifel
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Jefferies medical technology analyst holds analyst/industry conference call
- LivaNova’s Annual Meeting Strengthens Shareholder Alignment